Concerning the new Quinazoline platform patents, I have several questions for anyone knowledgeable on the topic. Reason given for new patents was to extend the length of the patent potection for 907 drug. Looks like it also broadens the reach for concept into many other disease areas. Does anyone expect CRIS to pursue development within areas other than cancers? Does CRIS still utilize mainland China lab to do its basic chemistry? Wonder if they already have preclinical drug candidates ready or in the works? Not very knowledgeable with chemistry or pharmacology. I am not saying I understand the dynamics of the patents (maybe some basics). Wondering if Cris could rework unprotected, old (generic type) drugs using the concept to improve drug effectiveness & get new patents? I am sure there are lots of old drugs out there that were very valuable at one time. I know this is just speculation, but it looks like there are possibilities to extend beyond cancer or am I wrong?
go to google message board and post there. Most reasonable/knowledgeable posters that were here, moved there.
Go to google, then click on finance (may have to access it from the "more" button on the main google screen, type Curis in the search area, and then scroll to bottom right for discussion group. Once there you can join to post or just read.